Foresta, Andreana https://orcid.org/0000-0002-6971-1674
Fernandez, Luisa Ojeda
Torrigiani, Ginevra
Schena, Simone
Roncaglioni, Maria Carla
Nobili, Alessandro
Tettamanti, Mauro
Franchi, Carlotta
Fortino, Ida
Succurro, Elena
Sesti, Giorgio
Baviera, Marta
Funding for this research was provided by:
Regione Lombardia (DGR 3375 del 14-07-2020, DGR 3375 del 14-07-2020, DGR 3375 del 14-07-2020, DGR 3375 del 14-07-2020, DGR 3375 del 14-07-2020, DGR 3375 del 14-07-2020, DGR 3375 del 14-07-2020, DGR 3375 del 14-07-2020)
Article History
Accepted: 20 December 2023
First Online: 17 February 2024
Declarations
:
: Andreana Foresta, Luisa Ojeda Fernandez, Ginevra Torrigiani, Simone Schena, Maria Carla Roncaglioni, Alessandro Nobili, Mauro Tettamanti, Carlotta Franchi, Ida Fortino, Elena Succurro, Giorgio Sesti, and Marta Baviera declare that they have no conflicts of interest.
: Not applicable.
: Not applicable.
: Not Applicable.
: Data that support the findings of this study are available by the Lombardy Region, but restrictions apply to the availability of these data and codes, which were used under license for the current study, and so they are not publicly available. Data are however available from the Lombardy Region upon reasonable request.
: This study was part of the EPIFARM-Pharmaco-epidemiology Agreement between the <i>Istituto di Ricerche Farmacologiche Mario Negri</i> IRCCS and the Lombardy region (Grant DGR 3375 del 14-07-2020).
: Access to row data is allowed only to the investigators within the Agreement between the Lombardy Region and the <i>Istituto di Ricerche Farmacologiche Mario Negri</i>. Row data cannot be shared out of that agreement according to the Regional Low Privacy. Programme code can be shared following permission granted from the Lombardy Region Health Ministry.
: Study concept and design: AF, MB, LOF, MCR, AN, GS, ES. Data acquisition: IF. Data analysis: GT, MT, SS. Data interpretation: AF, MB, LOF, MCR, AN, CF, MT, GS, ES. Drafting the manuscript: AF, MB, GS, ES. Critical revision of the manuscript for important intellectual content: LOF, MCR, AN, CF, MT, ES, IF. All authors approved the final version of the manuscript.